Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in ...

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential ...

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7 ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Building on the solid performance of 2024, Grifols (GRFS) forecasts continued success in 2025 with anticipated revenue growth and EBITDA ...

Grifols said it expects positive free cash flow to rise to €1.2-billion in 2029 and to €350 million-€400-million in 2025 ...

英为财情Investing.com - Grifols SA (NASDAQ: GRFS )星期三发布了第四季度的财报，数据显示，公司营收高于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$0.23，总营收为$2.03B，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$1.99B，每股收益为$0.20.

The Value Creation Plan presented at Capital Markets Day, CMD, is based on 3 pillars: Commercial Growth: Grifols (GRFS) plans to capitalize on ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care ...

BARCELONA, Feb 26 (Reuters) - Spanish drugmaker Grifols (GRLS.MC), opens new tab reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion ...

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...